Caladrius Biosciences Announces the Resignation of Joseph Talamo, Chief Financial Officer

NEXT STORY
ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update
PREV STORY
INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density

author_avatar
NASDAQ Market News

Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19

author_avatar
NASDAQ Market News

Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM)

author_avatar
NASDAQ Market News